Physician profile
John Michael Weston
NPI 1861474371
$14,142.94
in general payments reported to CMS, 2019-2025
56 companies · $2,254 in 2025
The $2,254 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,517 · 2020: $1,225 · 2021: $2,090 · 2022: $2,142 · 2023: $2,390 · 2024: $2,526 · 2025: $2,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,169.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,024.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,333.38 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,314.44 | 2019-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $1,262.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,022.95 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Lilly USA, LLC | $891.74 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $779.87 | 2019-2025 | Jardiance, Stiolto Respimat, Synjardy |
| Janssen Pharmaceuticals, INC | $750.80 | 2020-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $427.33 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $359.06 | 2022-2025 | |
| Abbott Laboratories | $342.15 | 2019-2025 | Freestyle Libre 3, Jot Dx |
| Pfizer INC. | $340.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $315.93 | 2019-2025 | |
| Dexcom, INC. | $283.22 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $235.34 | 2019-2024 | Dificid, Gardasil 9, Gardasil |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.